Cleared Traditional

K830652 - ANTI N DNA-HCP

K830652 is the FDA 510(k) clearance for ANTI N DNA-HCP by Immuno-Products Industries. It is a Class 2 Immunology device (product code KTL) cleared through the Traditional 510(k) pathway after a 17-day FDA review.

K830652 · Immuno-Products Industries · Immunology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Mar 1983
Decision
17d
Days
Class 2
Risk

K830652 is an FDA 510(k) clearance for the ANTI N DNA-HCP. Classified as Anti-dna Indirect Immunofluorescent Solid Phase (product code KTL), Class II - Special Controls.

Submitted by Immuno-Products Industries (Mchenry, US). The FDA issued a Cleared decision on March 24, 1983 after a review of 17 days - a notably fast clearance cycle.

This device falls under the Immunology FDA review panel, regulated under 21 CFR 866.5100 - the FDA immunology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Immuno-Products Industries devices

Submission Details

510(k) Number K830652 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received March 07, 1983
Decision Date March 24, 1983
Days to Decision 17 days
Submission Type Traditional
Review Panel Immunology (IM)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
87d faster than avg
Panel avg: 104d · This submission: 17d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code KTL Anti-dna Indirect Immunofluorescent Solid Phase
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.5100
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Immunology devices follow this clearance model.

Regulatory Peers - KTL Anti-dna Indirect Immunofluorescent Solid Phase

All 9
Devices cleared under the same product code (KTL) and FDA review panel - the closest regulatory comparables to K830652.
IGG ANTI-NDNA FLUORESCENT TEST SYSTEM
K013432 · Immuno Concepts, Inc. · Nov 2001
CRITHIDIA LUCILLIAE DS DNA KIT (DIAGNOSTIC USE)
K930987 · The Binding Site, Ltd. · Aug 1993
ANTI-NATIVE DNA ANTIBODY
K834349 · Sigma Chemical Co. · Apr 1984
CODE QAS 103 ANTI-DNA CONTROLS
K791354 · Amersham Corp. · Sep 1979